INTECH Investment Management’s Blueprint Medicines BPMC Stock Holding History

INTECH Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-31,834	Closed	-$4.08M	–	2418
2025 Q2	$4.08M	Sell	31,834 -8,180	-20%	-$850K	0.04%	409
2025 Q1	$3.54M	Buy	40,014 +8,443	+27%	+$824K	0.04%	441
2024 Q4	$2.75M	Buy	31,571 +13,060	+71%	+$1.2M	0.03%	540
2024 Q3	$1.71M	Buy	+18,511	New	+$1.84M	0.02%	543

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

INTECH Investment Management's BPMC Position: Q3 2025 in Review

INTECH Investment Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 31,834 shares — an estimated $4.08M sold.

INTECH Investment Management first reported a position in BPMC in Q3 2024 and held it in 4 quarters. The position peaked at $4.08M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

INTECH Investment Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
INTECH Investment Management sold 31,834 Blueprint Medicines shares in Q3 2025, an estimated $4.08M.
INTECH Investment Management first reported a position in Blueprint Medicines in Q3 2024 and held it in 4 quarters.
INTECH Investment Management's Blueprint Medicines position peaked at $4.08M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on INTECH Investment Management's 13F filing for Q3 2025, filed 12 Nov 2025.